Novavax CEO Erck bids adieu after 12 years, overseeing COVID vax development

Novavax CEO Stanley Erck heads off into retirement with a COVID vaccine authorization in hand, a critical achievement after 12  years at the helm building up the vaccine-focused biotech. The COVID milestone is—by far—his and the company’s crowning moment as Novavax looks to differentiate itself from market rivals Moderna and Pfizer. And he leaves behind a pipeline of other potential vaccines tackling viruses like influenza and RSV.